Reducing ADT to 18 Months May Be Sufficient in High-Risk Prostate Cancer June 7, 2017 Androgen deprivation therapy (ADT) can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to final results of a randomized phase III trial. However, the statistical design of the study may prevent firm conclusions on the best duration of treatment.Read more.Source: Cancer Network Prostate Cancer News
Androgen deprivation therapy (ADT) can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to final results of a randomized phase III trial. However, the statistical design of the study may prevent firm conclusions on the best duration of treatment.Read more.Source: Cancer Network
Complete the Survey
